Key Takeaways
- Tailored Outreach: Recruitment strategies must account for Parkinson's-specific challenges like limited mobility and the influential role of care partners.
- Multi-Channel Approach: Combining digital platforms, traditional media, and Patient Advocacy Groups (PAGs) ensures reach across different age demographics.
- Provider Partnerships: Building relationships with specialists is essential for identifying treatment-naive patients and securing referrals.
- Genetic Testing: Leveraging genetic screening can accelerate enrollment for precision medicine trials targeting specific mutations.
Understand the Parkinson’s disease patient population
Before deciding on an approach to patient recruitment for your Parkinson’s trial, it’s important to take stock of what you know and what you need to know about this patient population. Effective channel selection starts with a clear-eyed understanding of who the Parkinson's patient population is, not as a demographic abstraction, but in terms of how they navigate their condition, access care, and engage with information. For example, many people with Parkinson's disease may have difficulty with mobility or experience tremors, making it difficult to use certain digital channels. In older Parkinson's populations, digital engagement is often mediated through care partners rather than patients themselves.
This affects how outreach is designed, what consent and communication pathways need to accommodate, and where in the decision-making process different channels have the most influence. Understanding these details can help you tailor your recruitment strategies, communication channels, messaging, and imagery to reach the right people.
Selecting recruitment strategies based on patient needs
Based on what you know about the patient population and what outreach methods and messaging might resonate best, you can then select recruitment strategies for impact. These may include:
- Partnering with patient advocacy groups: Patient advocacy groups (PAGs) offer direct access to engaged patients and care partners who are already seeking information about disease management and trial opportunities. Patient advocacy groups can extend reach into communities that clinical sites rarely access directly, and their endorsement carries trust that sponsor-led outreach does not. Their effectiveness depends on how early they are engaged in the trial design process and whether messaging has been developed in genuine collaboration with the community. Partnering with these organizations extends reach into communities that are already informed about the disease and motivated to explore participation options.
- Utilizing social media and digital channels: Social media platforms like Facebook, Twitter, and Instagram, as well as online patient communities and forums, can be effective tools for reaching potential participants and their care partners. These platforms allow you to target specific demographics and interests, making it easier to reach people who are most likely to be interested in participating in a clinical trial. Social media and digital channels can also support participant retention by providing a consistent channel for trial updates, educational content, and questions from enrolled participants.
- Leveraging traditional advertising: Traditional advertising channels — newspapers, radio, and television — remain relevant for reaching older adults who are less active on digital platforms, particularly in geographies where print or broadcast media retain strong local readership or viewership. These channels can help reach older populations who may not be as active on social media or other digital channels.
- Building relationships with Parkinson's disease specialists and healthcare providers: Parkinson's disease specialists and healthcare providers can be valuable allies in recruiting participants for clinical trials. These providers have direct, longitudinal visibility into their patients' disease progression, symptom burden, and quality of life. They can help identify potential participants and make referrals to trial sites. Building relationships with these providers can be an effective way to increase enrollment in clinical trials.
- Considering genetic testing: Parkinson's disease has been found to have a genetic component, with mutations in several genes associated with the disease. Genetic testing can help identify individuals who are at higher risk of developing Parkinson's disease or who may have a genetic mutation associated with the disease. These individuals may be interested in participating in clinical trials for Parkinson's disease. Additionally, genetic testing can help identify potential participants for clinical trials that are specifically targeting individuals with a particular genetic mutation.
Conclusion
Enrollment is the rate-limiting step in Parkinson's trial success, and channel strategy is where that rate is either set or constrained. Channel selection in Parkinson's recruitment is not a post-protocol decision. It shapes who enters the funnel, at what rate, and how well screening conversion maps to actual trial eligibility. When recruitment channels are matched to the characteristics of the target patient population, trial teams are better positioned to reach eligible participants efficiently and reduce the risk of enrollment shortfalls.
For trials targeting genetically defined Parkinson's populations, Sano's platform connects genetic identification, participant recruitment, and long-term engagement within a single workflow, reducing the coordination burden across study teams. To review a detailed example of how this approach was applied in a Parkinson's study, the case study is available for download.